SF1670

SF1670 is a **potent and selective inhibitor of phosphatase and tensin homolog deleted on chromosome 10 (PTEN)**, with an IC50 of about 2 μM[1][3][5][9][10][11][12]. It acts by **binding to the active site of PTEN**, thereby inhibiting its phosphatase activity, leading to **increased intracellular PIP3 (phosphatidylinositol (3,4,5)-trisphosphate) signaling** and enhanced downstream Akt phosphorylation. PTEN is a critical negative regulator of the PI3K/Akt pathway, and its inhibition with SF1670 augments functional responses such as chemotactic migration, phagocytosis, superoxide formation, and polarization in neutrophils[2][3][5][7]. SF1670 has been shown in preclinical studies to enhance the efficacy of granulocyte transfusion in neutropenic models and to reduce apoptosis and inflammation via PTEN/Akt pathway activation[2][7]. It also inhibits PTPN2 and CD45 at lower potency[8][9]. SF1670 is a synthetic **small molecule** primarily used in research settings; it is not approved for clinical use.

Other names

PTP inhibitor XIX